Prodotti competitors / Area Oncology
NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals
- for adults with HER2-negative, high-risk early breast cancer who have inherited faults in their BRCA1 or BRCA2 genes, after surgery and chemotherapy
and
- for adults with previously treated hormone-relapsed metastatic prostate cancer who have the same BRCA mutations.
NICE expects to publish final guidance on olaparib for breast cancer and prostate cancer in May 2023.
More information at link
Grazie per il tuo feedback!